Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Inclusion Criteria: 1. Understand and voluntarily sign the informed consent form; 2. 18-70 years of age (inclusive); 3. Previously untreated CD19-positive large B-cell lymphoma; 4. Anticipated survival ≥12 weeks; 5. Adequate bone marrow reserve prior to apheresis 6. Appropriate organ function: 7. Eastern Cooperative Oncology Group (ECOG) Physical Status Score of 0 or 1; 8. Absence of CNS lymphoma; 9\. Negative blood/urine pregnancy test in women of childbearing age. Exclusion Criteria: 1. History of allergy to any of the components of the cell product; 2. History of stem cell transplantation; 3. History of organ transplantation; 4. Presence of active infections; 5. Current or history of central nervous system disorders; 6. Previous treatment with other modified T-cell therapy; 7. Previous treatment with anti-CD19/CD3 or other anti-CD19 therapies; 8. Malignancies other than those indicated for this trial; 9. History of any prior systemic immune checkpoint therapy; 10. History of short-acting cell growth factors or haematopoietic agonists/stimulants ; 11. History of a live vaccine within 3 months prior to screening;.